Loading quotes...
Forecast
| Buy |
Â
1 |
| Hold |
Â
2 |
| Sell |
Â
0 |
News Go to news feed
Bayer accelerates pharmaceutical research with new organizational model
Bayer is relying on the organizational model “Dynamic Shared Ownership,” which shifts decision-making authority to expert teams and reduces management layers. As a result, research, clinical development and market access work more closely together, significantly shortening time to commercialization. For the stroke drug Asundexian the model delivered a measurable advantage: the first approval in China and roughly a one-year lead over competitors. The success also raises the question of how much time the company lost previously. » More on faz.net
Bayer receives first approval for Asundexian in China
China has become the first country to approve the factor XIa inhibitor Asundexian (Sunharbo) for stroke prevention, the world’s first drug in this class. Bayer sees the approval as an important step toward market launch and expects significant sales; analysts estimate annual revenues of €1–3 billion. An accelerated approval in the US is imminent, while Europe may still have to wait two to three years depending on procedures and price negotiations. » More on faz.net
Bayer: positive Phase‑III data on Nubeqa push stock to top of DAX
Bayer reports from an interim analysis of the Phase‑III DASL‑HiCaP study that Nubeqa (Darolutamide) reduced the risk of metastasis or death (MFS‑CI) by 58 percent versus placebo after a median 3.8 years of follow‑up. Analysts see the results as adding sales potential of up to one billion euros for Nubeqa. In addition, China has approved the anticoagulant Asundexian (Sunharbo) for stroke prevention in patients after non‑cardioembolic ischemic stroke or high‑risk TIA, which could give the pharma business further room to grow. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 10.87B | 1.24% |
| Gross profit | 6.33B | 0.67% |
| Net profit | 219M | 210.05% |
| EBITDA | 1.91B | 461.00% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €44.77B |
Number of shares | 982.42M |
52-week high/low | €53.92 - €25.78 |
Dividend yield | 0.24% |
Dividends TTM | €0.11 |
Beta | 0.84 |
P/E ratio | -25.89 |
PEG ratio | 0.00 |
P/B ratio | 1.51 |
P/S ratio | 0.99 |
Company profile
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
| Name | Bayer |
| CEO | Bill Anderson |
| Headquarters | Leverkusen,
nw Germany |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| IPO | 12/16/1996 |
| Employees | 87,830 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | BAYZF |
XETRA | BAYN.DE |
Stuttgart | BAYN.SG |
MĂĽnchen | BAYN.MU |
Frankfurt | BAYN.F |
Berlin | BAYN.BE |
DĂĽsseldorf | BAYN.DU |
Hamburg | BAYN.HM |
London | 0P6S.L |
SIX | BAYN.SW |
Wien | BAYN.VI |
Milan | 1BAYN.MI |
Warschau | BAY.WA |
Wse | BAY.WA |